Summit Therapeutics Inc. Reports Q2 2026 Financial Results

What Happened

• Summit Therapeutics Inc. announced its financial results and operational progress for the quarter ended June 30, 2026 in a press release issued July 23, 2026. The company filed a Current Report on Form 8-K (Items 2.02 and 7.01) to disclose the results and related investor materials.
• Summit will host an earnings call at 4:30 p.m. ET on July 23, 2026 and has furnished the presentation slides to be used on the call. The Form 8-K was signed by Manmeet S. Soni, Chief Operating Officer, Chief Financial Officer and Director (Principal Financial Officer).

Key Details

• Filing date: July 23, 2026. Quarter reported: Q2 2026 (ended June 30, 2026).
• Press release furnished as Exhibit 99.1 to the Form 8-K.
• Presentation slides for the July 23, 2026 earnings call furnished as Exhibit 99.2.
• Earnings call scheduled for 4:30 p.m. ET on July 23, 2026; materials incorporated by reference in the 8-K.

Why It Matters

• The 8-K makes Summit’s latest quarterly results and operational update publicly available; investors can review the press release and slides for revenue, expense, pipeline or other financial details disclosed.
• The earnings call and provided slides offer timely management commentary on business performance and near-term plans; these materials are primary sources for assessing trends in quarterly results and the company’s operational progress.
• Because the filing furnishes the materials as exhibits, investors and analysts can access the exact press release and presentation used by management when evaluating Summit’s Q2 performance.